UBS Group AG Has $6.19 Million Stock Position in Medifast, Inc. (NYSE:MED)

UBS Group AG raised its position in Medifast, Inc. (NYSE:MEDFree Report) by 21.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 92,044 shares of the specialty retailer’s stock after acquiring an additional 16,260 shares during the period. UBS Group AG owned about 0.85% of Medifast worth $6,187,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. AQR Capital Management LLC raised its holdings in shares of Medifast by 18.7% in the 3rd quarter. AQR Capital Management LLC now owns 121,671 shares of the specialty retailer’s stock worth $9,107,000 after buying an additional 19,192 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Medifast by 22.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 166,210 shares of the specialty retailer’s stock worth $12,441,000 after buying an additional 30,329 shares in the last quarter. D.A. Davidson & CO. raised its holdings in shares of Medifast by 17.0% in the 3rd quarter. D.A. Davidson & CO. now owns 5,304 shares of the specialty retailer’s stock worth $397,000 after buying an additional 771 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Medifast by 301.1% in the 4th quarter. Exchange Traded Concepts LLC now owns 18,666 shares of the specialty retailer’s stock worth $1,255,000 after buying an additional 14,012 shares in the last quarter. Finally, Pacer Advisors Inc. raised its holdings in shares of Medifast by 62.9% in the 4th quarter. Pacer Advisors Inc. now owns 522,732 shares of the specialty retailer’s stock worth $35,138,000 after buying an additional 201,752 shares in the last quarter. 95.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. DA Davidson cut Medifast from a “neutral” rating to an “underperform” rating and dropped their target price for the stock from $25.00 to $17.50 in a report on Wednesday. TheStreet cut Medifast from a “c” rating to a “d+” rating in a report on Wednesday, February 21st.

View Our Latest Research Report on Medifast

Medifast Price Performance

MED stock opened at $21.85 on Friday. The business has a fifty day moving average price of $28.67 and a 200 day moving average price of $45.96. Medifast, Inc. has a fifty-two week low of $19.90 and a fifty-two week high of $109.52. The stock has a market capitalization of $239.04 million, a price-to-earnings ratio of 3.52 and a beta of 1.16.

Medifast (NYSE:MEDGet Free Report) last released its earnings results on Monday, April 29th. The specialty retailer reported $0.66 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.12). The firm had revenue of $174.74 million during the quarter, compared to analyst estimates of $168.90 million. Medifast had a net margin of 7.55% and a return on equity of 36.64%. The firm’s quarterly revenue was down 49.9% on a year-over-year basis. During the same period last year, the business posted $3.67 earnings per share. On average, equities analysts expect that Medifast, Inc. will post 0.95 earnings per share for the current fiscal year.

Medifast Company Profile

(Free Report)

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.

Further Reading

Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast, Inc. (NYSE:MEDFree Report).

Institutional Ownership by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.